However, the eligibility criteria can be complex, leading many to question: Is Semaglutide truly covered by HSAs
Constipation or diarrhea: Digestive changes occur in some patients, though less commonly than with GLP-1 medications
Clinical trials show that nausea affects approximately 44% of patients taking semaglutide (Wegovy) and about 24-40% of those on tirzepatide (Zepbound), with rates varying by dose
In particular, cortical microbleeds, often associated with cerebral amyloid angiopathy, are increasingly recognized as contributors to the pathogenesis of vascular epilepsy in older adults
Mild, transient erythema immediately after patch removal is common, but prolonged or severe reactions warrant medical review
GLP-1 Agonist Use Overview GLP-1 agonists are FDA-approved medications for managing Type 2 diabetes (T2D) because they lower blood sugar levels (15)(23)